hrcak mascot   Srce   HID

Izvorni znanstveni članak

COMPARISION OF COSTS OF SECONDARY PREVENTION AND TREATMENT OF STROKE – COST-EFFECTIVENESS ANALYSIS

Ivana Ceronja
Zvonko Šošić

Puni tekst: hrvatski, pdf (151 KB) str. 0-0 preuzimanja: 59* citiraj
APA 6th Edition
Ceronja, I. i Šošić, Z. (2011). USPOREDBA CIJENA SEKUNDARNE PREVENCIJE I LIJEČENJA MOŽDANOG UDARA – COST-EFFECTIVENESS ANALIZA. Liječnički vjesnik, 133 (9-10), 0-0. Preuzeto s https://hrcak.srce.hr/171846
MLA 8th Edition
Ceronja, Ivana i Zvonko Šošić. "USPOREDBA CIJENA SEKUNDARNE PREVENCIJE I LIJEČENJA MOŽDANOG UDARA – COST-EFFECTIVENESS ANALIZA." Liječnički vjesnik, vol. 133, br. 9-10, 2011, str. 0-0. https://hrcak.srce.hr/171846. Citirano 23.10.2019.
Chicago 17th Edition
Ceronja, Ivana i Zvonko Šošić. "USPOREDBA CIJENA SEKUNDARNE PREVENCIJE I LIJEČENJA MOŽDANOG UDARA – COST-EFFECTIVENESS ANALIZA." Liječnički vjesnik 133, br. 9-10 (2011): 0-0. https://hrcak.srce.hr/171846
Harvard
Ceronja, I., i Šošić, Z. (2011). 'USPOREDBA CIJENA SEKUNDARNE PREVENCIJE I LIJEČENJA MOŽDANOG UDARA – COST-EFFECTIVENESS ANALIZA', Liječnički vjesnik, 133(9-10), str. 0-0. Preuzeto s: https://hrcak.srce.hr/171846 (Datum pristupa: 23.10.2019.)
Vancouver
Ceronja I, Šošić Z. USPOREDBA CIJENA SEKUNDARNE PREVENCIJE I LIJEČENJA MOŽDANOG UDARA – COST-EFFECTIVENESS ANALIZA. Liječnički vjesnik [Internet]. 2011 [pristupljeno 23.10.2019.];133(9-10):0-0. Dostupno na: https://hrcak.srce.hr/171846
IEEE
I. Ceronja i Z. Šošić, "USPOREDBA CIJENA SEKUNDARNE PREVENCIJE I LIJEČENJA MOŽDANOG UDARA – COST-EFFECTIVENESS ANALIZA", Liječnički vjesnik, vol.133, br. 9-10, str. 0-0, 2011. [Online]. Dostupno na: https://hrcak.srce.hr/171846. [Citirano: 23.10.2019.]

Sažetak
Cerebrovascular accident (CVA) is a serious complication of untreated arterial hypertension. Introduction: The aim of this paper is to compare the cost of secondary prevention and treatment of CVA caused by untreated arterial hypertension. Methods: Cost-effectiveness analysis of diagnosis and therapy of arterial hypertension in comparison with CVA treatment. Results: The cost of secondary prevention of CVA per patient per year in 2006. was 1.589,19 kunas, which comes to 15.107,75 kunas in thirty years of treatment (discount factor included), whereas a single CVA treatment was 17.207,54 kunas on average. In every 850 treatments of hypertension (NNT) comes a prevented CVA which is 1.350.811,5 kunas, and is therefore more expensive than a single CVA treatment. Conclusion: Secondary prevention has a long-term protective effect improving the patients’ quality of life, inhibiting the potential post-CVA handicap and pre-retirement. Thus, the main advantage of both primary and secondary prevention is in their greater benefit for patients.

Ključne riječi
Hypertension – economics, diagnosis, therapy, complications; Stroke – economics, etiology, therapy, prevention and control; Cost-benefit analysis

Hrčak ID: 171846

URI
https://hrcak.srce.hr/171846

[hrvatski]

Posjeta: 150 *